Press Release - Glenmark

B/2, Mahalaxmi Chambers,
22, Bhulabhai Desai Road,
Post Box No. 26511,
Mumbai 400 026, India
including the highly regulated markets of USA and Europe. The formulation business
spans several product segments such as Dermatology, Internal Medicine, Paediatrics,
Gynaecology, ENT and Diabetes.
The Company in also engaged in cutting-edge research in discovering new molecules
and runs discovery projects in the areas of inflammation [Asthma/COPD, etc] and
metabolic disorders [Diabetes, Obesity, etc]. It recently announced the licensing of
its first Asthma/COPD molecule to Forest Labs and Teijin Pharma for the North
American and Japanese markets, respectively. This compound has subsequently
completed Phase I clinical trials successfully. [www.glenmarkpharma.com]
For further Information, please contact
Ms. Vaijayanti Karande
Senior Manager
[Corporate Communications]
Tel: 5654 9999 [Ext. 811]
Fax: 23519652
Email : vaijayantik@glenmarkpharma.com
2 of 2